Nano-X Imaging downgraded by Alliance Global Partners with a new price target
$NNOX
Medical Electronics
Health Care
Alliance Global Partners downgraded Nano-X Imaging from Buy to Neutral and set a new price target of $3.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/7/2026 | $3.00 | Buy → Neutral | Alliance Global Partners |
| 1/6/2025 | $23.00 | Buy | D. Boral Capital |
| 9/8/2023 | $14.50 | Buy | Alliance Global Partners |
| 1/5/2023 | $21.00 | Overweight | Cantor Fitzgerald |
4 - Nano-X Imaging Ltd. (0001795251) (Issuer)
New SCCT abstracts from Brigham and Women’s Hospital highlight the performance and clinical utility of Nanox.AI’s FDA-cleared cardiac AI solution, showing high agreement with expert assessment and its potential role in supporting guideline-directed preventive care. From incidental finding to clinical action: the AI INFORM randomized trial highlights how AI-detected coronary calcium may help clinicians identify opportunities for preventive lipid-lowering therapy. Nanox.AI Sponsors SCCT Scientific Session, "From Missed Finding to Missed Opportunity: Aortic Valve Calcification on Chest CT," Featuring Ofir Koren, MD, Cedars-Sinai Medical Center, on Sunday, July 12, at 7:30 am PETACH TIKVA, Is
PETACH TIKVA, Israel, June 11, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2026, before market open on Thursday, June 25, 2026. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q1 2026 Call Registration The live webcast of the conference call may be accessed
Initial deployment is expected to include six Nanox.ARC systems under a capex model PETACH TIKVA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (("Nanox", NASDAQ:NNOX), a leader in innovative medical imaging technology, today announced a distribution agreement with Top Med SAC ("Top Med") to deploy the Nanox.ARC system and related services in Peru. Under the agreement, Nanox appointed Top Med as its exclusive distributor of the Nanox.ARC system and Nanox platform in Peru, subject to commercial milestones and regulatory requirements. The agreement is structured as a capex model and includes an expected initial deployment of six Nanox.ARC systems, subject to receipt of t
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
SCHEDULE 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
20-F - Nano-X Imaging Ltd. (0001795251) (Filer)
Alliance Global Partners downgraded Nano-X Imaging from Buy to Neutral and set a new price target of $3.00
D. Boral Capital initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $23.00
Alliance Global Partners initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $14.50
4 - Nano-X Imaging Ltd. (0001795251) (Issuer)
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
NEVE ILAN, Israel, May 03, 2021 (GLOBE NEWSWIRE) -- NANOX IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, announced today the appointment of Moshe Shtengel as Chief Business Officer, effective May 2, 2021. Mr. Shtengel joins Nanox from Tuttnauer, a global manufacturer of sterilizers and infection control systems for medical institutions, where he served as Vice President of Global Sales, Marketing and Products. "Moshe is an extremely seasoned sales and business development executive with a proven track record of success and leadership in the medical field," stated Ran Poliakine, Chairman and Chief Executive Officer of Nanox. "As we
PETACH TIKVA, Israel, June 11, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2026, before market open on Thursday, June 25, 2026. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q1 2026 Call Registration The live webcast of the conference call may be accessed
Advanced commercialization in the US, signing multiple new customer and distribution agreements for Nanox.ARC and accelerated activities around Nanox.AI Management to host conference call and webcast Monday, April 20, 2026 at 8:30 AM ET Appointed new CFO effective August 1, 2026 PETAH TIKVA, Israel, April 20, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2025, and provided a business update. Recent Highlights: Generated $3.7 million in revenue in the fourth quarter of 2025, compared to $3.0 million in the fourth quarter o
PETACH TIKVA, Israel, April 06, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended December 31, 2025, before market open on Monday, April 20, 2026. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q4 2025 Call The live webcast of the conference call may be accessed by using t
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)